PROMACTA (GlaxoSmithKline LLC)


Welcome to the PulseAid listing for the PROMACTA drug offered from GlaxoSmithKline LLC. This Increased Megakaryocyte Maturation [PE],Increased Platelet Production [PE],Thrombopoietin Receptor Agonist [EPC],Thrombopoietin Receptor Agonists [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],UGT1A1 Inhibitors [MoA],UGT1A3 Inhibitors [MoA],UGT1A4 Inhibitors [MoA],UGT1A6 Inhibitors [MoA],UGT1A9 Inhibitors [MoA],UGT2B7 Inhibitors [MoA],UGT2B15 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: GlaxoSmithKline LLC
NON-PROPRIETARY NAME: eltrombopag olamine
SUBSTANCE NAME: ELTROMBOPAG OLAMINE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Increased Megakaryocyte Maturation [PE],Increased Platelet Production [PE],Thrombopoietin Receptor Agonist [EPC],Thrombopoietin Receptor Agonists [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],UGT1A1 Inhibitors [MoA],UGT1A3 Inhibitors [MoA],UGT1A4 Inhibitors [MoA],UGT1A6 Inhibitors [MoA],UGT1A9 Inhibitors [MoA],UGT2B7 Inhibitors [MoA],UGT2B15 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2008-11-24
END MARKETING DATE: 2019-04-30


PROMACTA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionPROMACTA from GlaxoSmithKline LLC
LABELER NAME: GlaxoSmithKline LLC
DEA SCHEDULE:
ACTIVE STRENGTH: 25(mg/1)
START MARKETING DATE: 2008-11-24
END MARKETING DATE: 2019-04-30
PRODUCT ID: 0007-4640_c7c46a73-1f77-45f6-ab60-1aa8f9e87463
PRODUCT NDC: 0007-4640
APPLICATION NUMBER: NDA022291

Other ELTROMBOPAG OLAMINE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
GlaxoSmithKline LLCPROMACTA
Novartis Pharmaceuticals CorporationPROMACTA